Retatrutide data strengthen Lilly’s hand in high-BMI obesity

Lilly again has the frontrunner in the weight loss Olympics: its triple agonist retatrutide showed greater Phase III obesity efficacy than Novo Nordisk’s dual-acting CagriSema, with a tolerability profile that does not appear markedly worse.

Investors had already seen a preview of retatrutide’s potential in December when Eli Lilly and Co. (NYSE:LLY) announced data from the Phase III TRIUMPH-4 study of retatrutide in obese patients with osteoarthritis that showed placebo-adjusted weight loss of up to 26.6%. ...